7 Keto's a metabolite of DHEA, which does have androgenic side affects such as increases levels of dihidrotestosterone. However, the metabolite 7-Keto, does not have this conversion, so you would not have to worry about the side affects. Here's some findings fro a site I got, but I had to cut a lot of it out due to charachter limits per post.
Heres some findings through studies: Taken fromhttp://www.humaneticscorp.com/7keto/7ketoabstracts.html#7ketoabstract15:
A Prospective, Randomized, Double Blind Study to Evaluate the Effect of Lean System 7ü on Body Composition
John L. Zenk, MD, Sandra A. Leikam, RN, Laurie J. Kassen, LD,RD, Michael A. Kuskowski, PhD
Background: 3-acetyl-7-oxo-dehydroepiandrosterone (7-oxo-DHEA) is a natural metabolite of dehydroepiandrosterone (DHEA) and has been shown to be effective in enhancing weight loss when combined with a diet and exercise program.
Objective: This study evaluated the effect of a formula containing 7-oxo-DHEA, citrus aurantium, coleus forskohlii, yerba mate, guarana, piper nigrum and dandelion leaf (Lean System 7Ö) on body weight, body composition, body mass index (BMI) and basal metabolic rate (BMR) in overweight patients on a weight reduction diet and exercise regimen.
Methods: In this prospective, randomized, double-blind, placebo-controlled trial, healthy, overweight adults were given Lean System 7 orally twice daily or an identical placebo and followed a calorie restricted diet and an exercise program for eight weeks. Body weight, BMI, BMR, waist and hip circumference, and body composition by dual energy x-ray absorptiometry (DEXA) were measured at baseline and week 8.
Results: Of 47 healthy, overweight adults enrolled, 35 completed the study (25 women, 10 men; age 26-45 years; BMI 27.0-38.9 kg/m▓). Patients taking Lean System 7 had a more significant decrease in hip circumference measurement after 8 weeks than those taking placebo. (mean ▒ SD loss, 4.85▒2.82 cm and 2.34▒2.33, respectively) (P=0.006). The intra-group analysis from baseline to study completion revealed that the Lean System 7 group had statistically significant (p=0.001) reductions in body weight, BMI, waist and hip circumference and the placebo group had significant (p=0.001) decreases in waist and hip circumference. There were no other statistically significant differences noted. Lean System 7 was well tolerated and there were no serious adverse events.
Conclusion: The results of this study reveal that when combined with a reduced calorie diet and a moderate exercise program, Lean System 7 was more effective at reducing hip circumference than exercise and diet alone.
The Effect of a Formula Containing 3-Acetyl-7-Oxo-Dehydroepiandrosterone on Weight Loss: A Randomized, Double-Blind, Placebo-Controlled Trial
John L. Zenk, MD, Tami R. Helmer, MD, Laurie J. Kassen, LD, RD, and Michael A. Kuskowski, PhD
A natural metabolite of dehydroepiandrosterone (DHEA), 3-acetyl-7-oxo-dehydroepiandrosterone (7-oxo-DHEA), has been shown to be effective in enhancing weight loss when combined with a diet and exercise program.
This study assessed the effects of a formula containing 7-oxo-DHEA, L-tyrosine, asparagus root extract, choline bitartrate, inositol, copper gluconate, manganese, and potassium iodide on weight loss, body composition, and basal metabolic rate (BMR) in overweight patients following a weight-reduction diet and exercise regimen.
In this prospective, randomized, double-blind, placebo-controlled trial, healthy, overweight adults were given the formula containing 3-Acetyl-7-Oxo-Dehydroepiandrosterone (200 mg/d) or a placebo or maltodextrin and followed a calorie-restricted diet (105 kJ/kg) and an exercise program for 8 weeks. Body weight, body composition (by bioelectric impedence), and BMR (by indirect calorimetry) were measured at baseline, week 4, and week 8. A thyroid panel was done at baseline and week 8.
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers
Objectives: To evaluate the safety and pharmacokinetics of 3-acetyl-7-oxo-DHEA (3▀-acetoxyandrost-5-en-7, 17-dione) given orally.
Method: The participants received placebo (n=6) or 3-acetyl-7-oxo-DHEA (n=16) at 50mg/d for 7 days followed by a 7-day washout; 100mg/d for 7 days followed by a 7-day washout; and 200mg/d for 28 days.
Results: There were no differences in the clinical laboratory values or in reported minor adverse experiences, between treatment and placebo groups. In general, blood hormone concentrations were unaffected by the treatment with 3▀-acetyl-7-oxo-DHEA and remained within the normal range. No changes in vital signs, blood chemistry or urinalysis occurred during treatment with 3▀-acetyl-7-oxo-DHEA compared to placebo. The administered steroid was not detected in the blood but was rapidly converted to 7-oxo-DHEA-S, the concentrations of which were proportional to dose. This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3▀-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200mg/d dose were 15.8 and 16.3 Ág/L respectively. The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours. The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.
Conclusions: These results indicate that 3▀-acetyl-7-oxo-DHEA is safe and well tolerated in normal healthy men at doses up to 200 mg/d for 4 weeks.